{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:42:26Z","timestamp":1794058946472,"version":"4.8.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1097\/fpc.0000000000000270","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T17:35:59Z","timestamp":1486661759000},"page":"164-167","source":"Crossref","is-referenced-by-count":70,"title":["PharmGKB summary"],"prefix":"10.1097","volume":"27","author":[{"given":"Alison E.","family":"Fohner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russ B.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri E.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210213","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00003088-198916040-00001","article-title":"Clinical pharmacokinetic properties of the macrolide antibiotics","volume":"16","author":"Periti","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"R2-6-20210213","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.mcna.2011.03.012","article-title":"Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline)","volume":"95","author":"Zuckerman","year":"2011","journal-title":"Med Clin North Am"},{"key":"R3-6-20210213","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R4-6-20210213","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/25.suppl_A.39","article-title":"Comparison of the acid stability of azithromycin and erythromycin A","volume":"25","author":"Fiese","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"R5-6-20210213","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infect Dis Clin North Am"},{"key":"R6-6-20210213","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.106.014407","article-title":"The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3","volume":"35","author":"Seithel","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R7-6-20210213","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol Ther"},{"key":"R8-6-20210213","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/106002809202600112","article-title":"The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin","volume":"26","author":"Bahal","year":"1992","journal-title":"Ann Pharmacother"},{"key":"R9-6-20210213","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1124\/dmd.108.022285","article-title":"Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat","volume":"36","author":"Garver","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R10-6-20210213","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-014-0209-3","article-title":"Interethnic differences in pharmacokinetics of antibacterials","volume":"54","author":"Tsai","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R11-6-20210213","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clpt.2006.06.002","article-title":"The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity","volume":"80","author":"Kurnik","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R12-6-20210213","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.48.3.809-814.2004","article-title":"Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin","volume":"48","author":"Sugie","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-6-20210213","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2174\/1389200215666140605130935","article-title":"A 30-years review on pharmacokinetics of antibiotics: is the time right for pharmacogenetics?","volume":"15","author":"Baietto","year":"2014","journal-title":"Curr Drug Metab"},{"key":"R14-6-20210213","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2125.2000.00261.x","article-title":"Macrolide-induced clinically relevant drug interactions with cytochrome p-450 A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin","volume":"50","author":"Westphal","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R15-6-20210213","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00228-010-0869-3","article-title":"Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism","volume":"66","author":"Shi","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-6-20210213","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1734-1140(09)70140-9","article-title":"Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects","volume":"61","author":"He","year":"2009","journal-title":"Pharmacol Rep"},{"key":"R17-6-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-800173-8.00001-5","article-title":"Azithromycin","volume":"39","author":"Bakheit","year":"2014","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"R18-6-20210213","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"R19-6-20210213","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkr159","article-title":"Hepatic safety of antibiotics used in primary care","volume":"66","author":"Andrade","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R20-6-20210213","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/clpt.2011.25","article-title":"Effect of ABCC2 (MRP2) transport function on erythromycin metabolism","volume":"89","author":"Franke","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R21-6-20210213","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.2012.106","article-title":"OATP1B1 polymorphism as a determinant of erythromycin disposition","volume":"92","author":"Lancaster","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R22-6-20210213","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clpt.2006.06.006","article-title":"Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation","volume":"80","author":"Colombo","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R23-6-20210213","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"R24-6-20210213","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J Pathol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:46Z","timestamp":1620951826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201704000-00006"}},"subtitle":["Macrolide antibiotic pathway, pharmacokinetics\/pharmacodynamics"],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000270","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}